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ABSTRACT 
 
MEGGAN M.H. WEHMEYER: Impact of Periodontal Therapy on Metabolic and 
Inflammatory Markers in Patients with End Stage Renal Disease 
(Under the direction of Steven Offenbacher) 
 
Objective: To test whether periodontal intervention in dialysis patients with periodontal 
disease will result in improvement of inflammatory and metabolic markers compared to no 
treatment.  Methods: Fifty-one dialysis patients with moderate to severe periodontal disease 
were recruited from six dialysis units. Twenty-five subjects were randomized to a periodontal 
treatment arm and twenty-six subjects were randomized to a control arm. Clinical periodontal 
parameters and serum were collected at baseline, 3 months and 6 months. Serum was 
analyzed for interleukin-6 and serum albumin. Results: Compared to untreated control, 
periodontal therapy was associated with a statistically significant improvement in clinical 
parameters of periodontal disease at 3 months, but not at 6 months and was not associated 
with any difference in serum interleukin-6 or serum albumin. Conclusion: Periodontal 
therapy was associated with improved clinical measures of periodontal disease, but not with 
improved interleukin-6 or serum albumin in this population. Diabetic status, plaque control 
and obesity should be tightly controlled in future studies of periodontal therapy in this 
population. 
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CHAPTER 1. INTRODUCTION 
The burden of cardiovascular disease (CVD) is heavy among patients with chronic 
kidney disease (CKD).  Myocardial infarction, sudden death, or stroke, remain leading causes 
of death and disability, especially for those patients receiving dialysis therapy [1, 2].  
Traditional risk factors [3] only partially explain the burden of CVD [4]. Previous studies 
have explored the potential role of periodontal disease in explaining the excess burden of 
CVD in the CKD population.  Periodontitis is an inflammatory disease caused by an 
infection of predominately gram negative organisms [5] and has been well-studied in other 
populations as a CVD risk factor [6-21].  A very high prevalence of periodontal disease in 
patients with various stages of CKD has been observed [22, 23].  Elevated systemic 
inflammatory markers is common to CVD, CKD and periodontal disease [24-32] 
 Treatment of periodontal patients with scaling, root planning, and flurbiprofen is 
associated with a trend to reduction of systemic inflammatory markers one year after therapy 
[28] and successful treatment of periodontitis is related to statistically significant reductions 
in systemic inflammatory markers CRP and IL-6 [32].  Recent data have also shown that the 
improved control of periodontitis achieved with local delivery of antibiotics leads to 
adjunctive systemic benefits [33]. The present paper presents findings from an exploratory, 
randomized, controlled intervention study to assess study feasibility and to determine 
whether the treatment of periodontal disease in maintenance dialysis patients reduces a 
prominent marker of systemic inflammation (serum Il-6) and improves a marker of nutrition 
(serum albumin)
 
 
 
 
CHAPTER 2. BACKGROUND AND SIGNIFICANCE 
Periodontal Disease 
Periodontal disease is a destructive inflammatory process of the supporting structures of 
the teeth including the gingiva, periodontal ligament and alveolar bone.  Clinical measures to 
assess periodontal health include pocket depth (PD) and gingival recession; where PD refers 
to the depth of the pocket measured from the cementoenamel junction (CEJ) to the depth of 
the gingival sulcus, and gingival recession is the distance from the marginal gingival (GM) to 
the CEJ.  Clinical attachment level (CAL) is calculated from the sum of PD and GM-CEJ 
measurements and forms the basis for the currently accepted periodontal disease 
classification system [34]. 
Chronic periodontitis is an infection of predominately gram-negative bacteria, including 
Porphyromonas gingivalis, Tannerella forsythia, Treponema denticola, and others (Philstrom 
et al 2005).  Often painless and insidious in onset, it frequently is not diagnosed until it is 
severe and extensive. Characteristics of a healthy periodontium include pink, scalloped 
gingiva, well defined interdental papilla, 1-3mm probing depths, no clinical attachment loss, 
alveolar bone levels 1-2mm apical to the CEJ, and a lack of bleeding on probing. 
Characteristics of a diseased periodontium include loss of gingival stippling (indicating 
edema), erythema, blunting of papilla, radiographic bone height more than 3mm from the 
CEJ, probing depths greater than 4mm, clinical attachment loss and presence of bleeding on 
probing.  
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Periodontal disease is classified as generalized (30% of sites) or localized (<30% of 
sites) and slight (1-2mm clinical attachment loss), moderate (3-4mm clinical attachment loss) 
and severe (≥5mm clinical attachment loss) [34]. The prevalence of severe periodontal 
disease is about 5 times greater in the dialysis population (and to a lesser extent in the CKD 
population) than in the general population [23, 35, 36]. 
 
Chronic Kidney Disease and End Stage Renal Disease 
The kidney serves several vital functions.  It maintains salt/water and acid/base 
homeostasis and removes nitrogenous waste products.  The kidney also produces hormones 
necessary for red blood cell synthesis and calcium absorption.  Kidney disease refers to an 
impairment of normal kidney function. Kidney disease is often divided into two broad 
categories.  Acute kidney injury refers to the rapid loss of renal function over days to weeks.  
Chronic kidney disease is a progressive loss of function occurring over several months to 
years.  
Chronic kidney disease is categorized based on the level of impairment of the 
glomerular filtration rate (GFR).  Stage one is early disease, while stage five represents 
severe disease necessitating renal replacement therapy (dialysis), and is often called end-
stage renal disease (ESRD).  
 
The burden of CVD is high in the CKD population 
Cardiovascular disease continues to be a major chronic health problem in the general 
population.  Mortality and morbidity from CVD are arguably the major chronic health 
problems in the CKD population. 
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Data from the 2006 annual report of the United States Renal Data System (USRDS) 
quantify the burden of CVD [1].  At the start of dialytic therapy, 31.9% of patients report 
congestive heart failure, 25% coronary artery disease, 8.2% acute myocardial infarction, 
6.5% cardiac dysrhythmia, 9.0% cerebrovascular disease, and 13.8% peripheral vascular 
disease.  While the USRDS relies primarily on self-reporting, recent prospective, rigorously 
conducted surveys seem to confirm the high prevalence of CVD.  A major randomized 
clinical
 
trial, the Hemodialysis (HEMO) Study revealed that 40% of prevalent hemodialysis 
patients have coronary artery disease, 19% have cerebrovascular disease, and 23% have 
peripheral vascular disease [37]. The Choices for Healthy Outcomes in Caring for End-Stage 
Renal Disease (CHOICE) study found that 45% of prevalent hemodialysis patient had 
ischemic heart disease, 18% had cerebrovascular disease, and 30% peripheral vascular 
disease [38].   
Historically, CVD mortality is approximately 10-20 times higher among ESRD patients 
compared to the general population [27].  Cardiovascular mortality accounts for nearly 50% 
of overall mortality in the dialysis population [1].  The overall death rate was 229.4 per 1000 
patient years; CVD accounted for 107.6 events (CVD deaths defined as AMI, atherosclerotic 
heart disease, cardiomyopathy, cardiac arrhythmia, cardiac arrest, pulmonary edema, 
congestive heart failure, and cerebrovascular disease). The next largest cause of death was 
septicemia (25.0 events per 1000 patient years). 
An editorial by the editor of Arteriosclerosis, Thrombosis and Vascular Biology, noted 
that  “The conventional risk factors for atherosclerosis are well understood, but they can 
account for only about 50% to 70% of atherosclerotic events in the general population” [39].  
Risk factors for CVD observed in the general population do not necessarily extrapolate to the 
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CDK populations, especially those with ESRD.  In fact, conventional risk factors may 
account for even lower percentage of atherosclerotic events.  Again, both the HEMO and 
CHOICE studies revealed that traditional risk factors were not associated with CVD [37, 38, 
40]. Interestingly, the CHOICE study made a case for inflammation confounding the 
association of a traditional risk factor, elevated serum cholesterol, with CVD [40].  
Periodontal disease is a source of inflammation and an avenue for bacteremia. A report by 
Ishani, Collins et. al reported that septicemia appears to be an important and potentially 
preventable cardiovascular risk factor in dialysis patients [41].  In addition, vascular 
calcification as a consequence of altered phosphate and calcium balance are proving to be a 
novel risk factor for CVD in this population.  
 
Periodontal disease is an independent risk factor for CVD 
Periodontal disease contributes to the development of the systemic inflammatory 
response and accelerates atherosclerosis.  Inflammation and infection are putative risk factors 
for atherosclerosis.  Periodontal disease is a candidate risk factor that results in a vigorous 
localized inflammatory, as well as systemic inflammatory response. 
Biofilms in the oral cavity on soft and hard tissues contain greater than 10
10
 organisms 
[5].  Many of these organisms are pathogenic and, upon evasion of local host defenses, elicit 
local inflammation as well as gain access to the circulation they also induce systemic 
inflammation. Within the local periodontal tissues, monocytes, dendritic cells and other 
immune cells recognize lipopolysaccharides in the bacterial cell wall and other toll-like 
receptor (TLR)-agonists and secrete various inflammatory mediators, including prostaglandin 
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E2 (PGE2), interleukin 1 beta (IL-1), interleukin 6 (IL-6), and tumor necrosis factor alpha 
(TNF) [29, 42].  
Evidence from human studies demonstrate that periodontal disease can induce a systemic 
inflammatory response and is associated with cardiovascular risk factors including acute 
phase proteins, CRP, and plasma fibrinogen [14, 43, 44]. Using data from the NHANES III 
and the ARIC studies, individuals with periodontitis were found to have increased systemic 
levels of CRP and fibrinogen. Levin et al (2004) note that the single most used marker for 
inflammation is C-reactive protein (CRP). It has been linked epidemiologically to nutritional 
state and its markers [24, 45, 46], cardiovascular risk factors [22, 47], cardiovascular disease 
[30, 40, 48-51], and morbidity and mortality [25, 31, 40, 48, 52-55] in patients with chronic 
kidney disease (CKD), most notably in CKD stage five or end-stage renal disease (ESRD). 
These associations remained statistically significant after adjustment for multiple 
periodontal and CVD risk factors.  Case control studies have shown that CRP levels were 
elevated in patients with periodontal disease as compared to periodontally healthy individuals 
[28, 56, 57].  In addition, pilot results indicated that periodontal treatment may reduce CRP 
levels [58].  Treatment of periodontal patients with scaling, root planning, and flurbiprofen is 
associated with a trend to reduction of CRP levels one year after therapy [28]. Successful 
treatment of periodontitis is related to statistically significant reductions in CRP and IL-6 
[32]. 
The effects of systemic dissemination of bacteria from periodontitis results in hepatic 
activation of the acute phase response with increases in CRP and IL-6 [59-61]. Moreover, 
these bacteria are also capable of invading the endothelial lining of the major elastic arteries 
[59-61].  Both PCR nucleotide signals and viable bacteria are detectable within atheromatous 
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plaques [62, 63]. Consequently, these bacteria in combination with inflammatory cytokines 
and acute phase reactants are believed to contribute to an acceleration of systemic 
atherosclerosis [64-66] and the development of clinical CVD. In experimental models, 
periodontal pathogens have been shown to promote platelet aggregation, foam-cell 
formation, and the development of atheromas [67-69]. The mechanism by which this may 
occur remains elusive but may be a consequence of the production of antibodies to 
periodontal bacteria, including antibodies to bacterial heat shock proteins (HSPs) that cross-
react with HSPs of the heart and may contribute to atheroma formation [70],  a decrease in  
anti-atherogenic potency of HDL cholesterol by periodontitis,  or enhanced macrophage 
activation by mean of increased serum lipopolysaccharide production [18, 71, 72]. 
 
Chronic kidney disease strengthens the association of periodontal disease and 
preclinical atherosclerosis 
Data from the Dental ARIC study demonstrates how underlying kidney disease  
strengthens the relationship of periodontal disease and preclinical atherosclerosis [23]. A 
cross-sectional study of 5702 middle-aged black and white men and women was conducted.  
Periodontitis was determined by a clinically-derived definition [73], and categorized as 
healthy/gingivitis, initial, and severe.  Renal insufficiency was defined as glomerular 
filtration rate (GFR) < 60 ml/min/1.73 m
2
. Compared to mild/none periodontal disease, 
severe periodontal disease was associated with intima media thickness (IMT) in a group of 
participants with GFR < 60 ml/min. The odds ratio, with 95% C.I. was 3.2 (1.5-6.9, 
p=0.004).  In individuals with GFR > 60 ml/min, there was no association observed between 
periodontal disease and carotid IMT. 
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Periodontal disease is associated with CVD morbidity and mortality During the last 15 
years a substantial number of population-based, clinical, laboratory, and animal studies have 
been published that reported findings of a possible periodontal disease and cardiovascular 
disease relationship.  The bulk of evidence suggests an association between periodontal 
disease and heart disease [6-21]. Yet because these studies were performed primarily in the 
general population, we feel that the strength of associations would be at a level considered 
moderate. In the CKD population, especially in the ESRD population, the burden of CVD is 
high enough to expect a stronger association.  Whether treatment of periodontal disease 
reduces risk of cardiovascular events still remains unclear [74-76].   
 
Moderate to severe periodontal disease predicts cardiovascular mortality among ESRD 
patients   
A recent study investigated mortality (CVD and all-cause) over 18 months by 
periodontal disease status [77].  One-hundred patients had mild or no periodontitis; 68 had 
severe-to-moderate disease. During the follow-up period there were a total of 22 deaths, 14 
of which were from cardiac causes. Adjustment for age, center, dialysis vintage, smoking, 
diabetes mellitus, and hypertension did not diminish the strength of association between 
periodontal disease and mortality, hazards ratio of 4.8 (95% C.I. 1.3-17.7).  
 
The burden of periodontal disease is high in the CKD population 
Data suggest that the burden of periodontal disease is high in the CKD population, 
especially among those with ESRD.  Studies suggest that the prevalence of periodontal 
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disease and severity of kidney disease are positively related. One such study was performed 
in the Third National Health and Examination Survey to examine the association of 
periodontal disease and kidney disease [35]. Because of the nature of the periodontal exam 
(half-mouth exam in NHANES III versus full mouth in D-ARIC), a slightly different 
definition of periodontal disease was used.  The definition, periodontal pocketing depth (PD) 
status, and was divided into three categories: none (0 sites with pocket depth, PD, 4+ 
millimeters), moderate (1 to 8 sites with PD 4+ mm), or extensive (>8 sites with PD 4+ mm).  
Renal insufficiency was defined as high serum creatinine > 1.3 mg/dl. Extensive pocketing 
was associated with increased odds of high serum creatinine (1.36, 95% C.I. 1.07-1.60) 
compared to no pocketing, after adjusting for demographic and medical covariates. 
An additional study performed using D-ARIC data [78] examined whether serum 
antibodies to oral periodontal pathogens were associated with renal insufficiency.  Serum 
antibodies represent better evidence of invasive periodontal disease compared to the standard 
measures of attachment loss and/or pocket depths. Oral biofilm microbial composition was 
performed by DNA checkerboard and serum antibody IgG titers to specific bacteria by 
immunocheckerboard.  Levels of serum IgG to specific oral bacteria were categorized by 
quartiles as high titer (comparing upper versus lower three) and eGFR<60 as the dependent 
variable in logistic regression models.  High levels of serum IgG to selected periodontal 
pathogens including Porphyromonas gingivalis, Treponema denticola and Aggregobacter 
actinomycetemcomitans were associated with an increased risk for eGFR<60mL/min/1.73 m
2
 
when adjusted for race, center, age, gender, education, diabetes, hypertension, LDL  
cholesterol, HDL cholesterol, triglycerides, BMI (adj OR 1.6-1.7, P<0.05). 
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Inflammation/malnutrition in the CKD population 
Inflammation and malnutrition are common in the ESRD population. The prevalence of 
elevated inflammatory markers is high, between 30% and 60% of North American and 
European dialysis patients [51, 54, 55, 79]. Protein energy malnutrition affects from 23% to 
76% of hemodialysis patients, and 18% to 50% of peritoneal dialysis patients [40, 79].  
Importantly, inflammation may be highly episodic.  For example, both acute phase proteins 
CRP and albumin vary over time [45], albumin considerably less so than CRP. 
The potential causes of the high inflammatory burden and malnutrition are not known but 
likely to be multifactorial: possibly related to dialysis technique (i.e. exposure to dialyzer 
membrane), or to the accumulation of pro-inflammatory compounds in renal failure (AGE’s, 
beta2 microglobulin) or to the loss of defense mechanism to oxidative stress.  
Clinically apparent and occult infection are common in the dialysis population, yet are 
not often considered as potential sources of inflammation.  Periodontal disease, one of the 
major types of infection-driven inflammation, has not hereunto been extensively studied in 
hemodialysis/ESRD patients.  Preliminary evidence suggests further investigation because of 
the abundance of this disease in the dialysis population, and the fact that it is associated with 
an important marker of inflammation, nutrition, and mortality. 
Despite a poor understanding of the potential mechanisms/causes of inflammation, these 
markers are strongly predictive of mortality and morbidity in the dialysis population.  
Hypoalbuminemia and CRP have been demonstrated to be strong predictors of death [46, 80-
82].  Severe periodontal disease is strongly associated with low serum albumin among ESKD 
patients.  In a study [83] of 154 patients undergoing maintenance hemodialysis, thirty-five 
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subjects had severe periodontitis.  Severe periodontitis was associated with low serum 
albumin, odds ratio = 8.20 (p=0.01; 95% Confidence Interval: 1.61-41.82) compared to 
individuals without severe periodontitis disease after adjustment for age, gender, race, 
diabetes mellitus, hypertension, body mass index, smoking, study site, total cholesterol, 
serum calcium, serum phosphorus, and normalized protein catabolic rate.  Serum albumin
 
is 
one of the key indicators of dialysis quality [84]. Hypoalbuminemia
 
has been demonstrated to 
be a strong predictor of death [85].
 
 
Summary 
The model of periodontitis, a plaque-induced inflammatory disease, contributing to 
systemic inflammation and accelerated atherosclerosis and clinical CVD is well described.  
There is also ample evidence that inflammation and CVD are common in the CKD 
population.  Complications from CVD continue to be the leading cause of death in the ESRD 
population.  The underlying causes of CVD in this population are still not fully understood. 
The primary objective of this study was to conduct a randomized interventional small 
exploratory study to test the hypothesis that periodontal intervention in dialysis patients who 
have both periodontal disease and a historically high burden of cardiovascular disease will 
result in a reduction of inflammatory markers and an improvement in metabolic markers.  
These markers are known to predict mortality [46, 80-82].   
 
 
 
 
 
 
 
 
CHAPTER 3. MATERIALS AND METHODS 
Subjects   
 Hemodialysis and peritoneal dialysis patients were recruited from the University of 
North Carolina Hospital Affiliated Dialysis Units at Carrboro, Pittsboro, Siler City and 
Fresenius Medical Care Units in Carrboro, Pittsboro, Siler City and Durham, North Carolina 
from July 2008 through December 2009. All subjects met the following inclusion criteria: 
presence of moderate to severe periodontal disease (2 or more teeth with at least 6 mm CAL 
and at least 1 site with PD > 5 mm), receiving dialysis for at least three months, presence of 
end stage renal disease (GFR ≤15ml/min/1.73m2), English speaking, ability and willingness 
to give written informed consent for participation in the study, age 18 to 80 years, and 
presence of twelve or more teeth.  
 Subjects were excluded if they had the following:  any severe co-morbid conditions 
likely to affect life expectancy within 1 year (for example, metastatic cancer), any condition 
that would, in the judgment of the clinician or patient’s physician, be a contraindication to 
dental treatment, dementia, pregnancy or lactation, inability to take oral medications, allergy 
or intolerance to minocycline, tetracyclines or polygycolate polymers, allergy to both 
penicillin and clindamycin, severe dental caries, pulpal or mucosal disease that would 
interfere with periodontal therapy, inability or unwillingness to follow the study protocol. 
Written informed study consent and HIPAA consent were obtained from all subjects prior to 
study inclusion. The study was approved by the Biomedical Institutional Review Board of 
the University of North Carolina.  
13 
 
Subjects were blindly randomized (1:1) to either the treatment or control group using 
randomization codes generated by the study statistician. The treatment group received 
periodontal therapy following baseline, while the control group received periodontal therapy 
at the conclusion of the study (6 months).  All subjects were appointed for a baseline visit at 
the General and Oral (GO) Health Clinic, a clinical research facility at the dental school in 
Chapel Hill, NC. All study appointments occurred on the subject’s inter-dialysis day with the 
exception of peritoneal subjects. 
 
Study Groups 
Those randomized to the periodontal treatment group received periodontal therapy 
following baseline. Those randomized to the control group received delayed periodontal 
therapy at the conclusion of the 6 month follow up appointment. Systemic oral antibiotics 
(2mg amoxicillin or 600mg Clindamycin if patient had an allergy to amoxicillin) were 
administered by the examiner prior to the periodontal therapy appointment only in order to 
minimize the effect of any transient bacteremia on the patient’s dialysis catheter. Antibiotics 
were not administered at any other appointment. Periodontal treatment consisted of the 
removal of periodontal organisms and other dental deposits by intensive supra- and 
subgingival scaling and root planning under local anesthesia by quadrant using hand and 
ultrasonic instruments as needed. Adjunctive subgingival antimicrobial therapy (Arestin
®
, 
FDA approved and marketed by J&J) that provides controlled release of microsphere-
encapsulated, biodegradable minocycline was administered to all sites with >5 mm probing 
depths.  Any teeth deemed hopeless (gross decay, severe bone loss, abscess, etc.) were 
extracted at the time of scaling and root planing in the quadrant.  Treatment was done in one 
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or two appointments by one of three providers (two hygienists and one periodontology 
resident). 
Control group subjects received follow up examinations at 3 and 6 months after baseline; 
treatment group subjects received follow up examinations at 3 and 6 months after completion 
of therapy. Those in the treatment group received administration of Arestin to any site with 
residual PD >5mm at 3 and 6 month follow up appointments.  
 
Participant Training  
 All subjects received verbal and written oral hygiene instruction (downloaded from 
ADA website  at http://www.ada.org/public/topics/cleaning_faq.asp on February 4, 2008) 
during each visit. Each subject was instructed to use a soft bristled toothbrush two times per 
day using the modified Bass sulcular brushing technique and to floss once per day using the 
c-wrap technique. A demonstration was given using a large scale dental model and 
toothbrush and floss as well as in the patient’s mouth using a hand mirror. Each subject was 
asked to demonstrate their understanding by replicating the modified Bass brushing 
technique and the C-wrap flossing technique in their own mouth. 
 
Clinical Parameters 
Examiners were calibrated for accuracy and repeatability against a gold standard. An 
initial calibration with all examiners was performed followed by yearly re-calibrations.  
Percent agreement with the Gold Standard was above 90% for pocket depth and attachment 
loss measurements and Kappa scores were above 0.90. Medical histories were reviewed and 
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updated at every appointment. The following parameters were assessed on all subjects at 
baseline, 3 months and 6 months. 
Plaque Index (PI): The plaque and stain index was scored for three facial surfaces 
(distofacial, facial, mesiofacial) and the direct lingual surfaces of each tooth using the Silness 
and Löe index.  The tooth surface to be scored was air dried and not disclosed.   
Gingival Index (GI): The gingival index was scored on three facial surfaces (distofacial, 
facial, mesiofacial) and the direct lingual surfaces using the Löe and Silness Index following 
a 1mm subgingival sweep.   
Probing Depth (PD):  A manual periodontal probe (UNC-15) was used to measure 
probing depth (PD) at 6 sites per tooth for all teeth present in the mouth.  PD was measured 
from the free gingival margin to the base of the pocket, and was recorded in whole 
millimeters (rounded down to the nearest millimeter.) 
Clinical Attachment Level (CAL): Clinical attachment level was calculated for 6 sites per 
tooth on all teeth present in the mouth using the formula  probing depth  measurement minus 
gingival margin to CEJ measurement  (where a gingival margin coronal to the CEJ is 
recorded as a positive number and a gingival margin apical to the CEJ is recorded as a 
negative number, rounded down to the nearest millimeter.)   
Bleeding on Probing (BOP):  BOP was assessed and recorded after probing 
measurements and CAL are taken for each quadrant. BOP was recorded for six sites per tooth 
for all teeth present in the mouth.   
A 14-radiograph periapical series was obtained to assess additional pathology and 
referrals for treatment were made as needed. 
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Serum Albumin and IL-6 measurements 
Venous blood (2 vials of 5-7 ml each) was collected under sterile technique.  Blood 
was processed into serum within 2 hours after collection: the whole blood was kept at room 
temperature for 30-45 minutes to allow a clot to form, and then centrifuged for 12 minutes to 
separate the serum from the clot.  Serum was then aliquoted into barcode labeled microfuge 
tubes and quickly frozen at -80°C and stored until analysis. Serum was blindly analyzed for 
hsIl-6 by the UNC GCRC BAC lab, and serum albumin was blindly analyzed by the UNC 
Hospital McLendon Lab. Interleukin 6 was assayed by high-sensitivity enzyme-linked 
 immunofluorescent assay (R&D Systems, Minneapolis, MN). The ELISA results (hsIL-6) 
were obtained with a SpectraMax M2 from Molecular Devices (Sunnyvale, CA).   Serum 
Albumin was analyzed via colorimetric assay on a dry slide (Ortho Johnson and Johnson, 
Rochester, NY). 
 
Statistical Considerations 
A sample size of 25 per treatment group at six months follow-up was calculated to 
provide 80% power to detect statistically significant differences in the mean levels of the 
primary outcomes between the two treatments that are as small as seventy-nine percent of the 
applicable standard deviation, using two-sided 0.05 significance tests. The estimated standard 
deviation of serum albumin is 0.53, and the minimum detectable difference is 0.42.  These 
power calculations were based upon a simple two group comparison of a single outcome 
variable at the six month follow-up visit with the independent t-test.   
The main purpose of this study was to compare serum albumin and Il-6 for treatment vs. 
no treatment in patients with periodontal disease and receiving renal dialysis for at least 3 
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months. Additional variables considered included age (years), gender (male or female), BMI 
(kg/m
2
), diabetic status (diabetic or not), dialysis type (hemodialysis or peritoneal dialysis), 
smoking status (current smoker or non-smoker), and a personal medical history of heart 
disease (known history or no known history).   
Statistical analysis was performed using the SAS program (SAS 9.1.3, SAS Institute Inc., 
Cary, NC, US). Exploratory univariate data analyses were conducted to examine the 
distributions of periodontal disease parameters, co-morbid variables (diabetes, smoking, 
BMI, age, race, dialysis vintage and gender), and the outcome variables and to inspect for 
outliers and missing data. This was done by means of plots (horizontal bar charts, box plots, 
and normal probability plots) and test statistics.  Outliers were detected and checked for 
accuracy. Analysis with outliers (more than two standard deviations from the mean) excluded 
did not significantly alter conclusions for any outcome parameter. Analysis included means 
and standard deviation for continuous variables and percents for categorical variables. 
Baseline comparisons between treatment groups were done using chi-squared tests and t-
tests, as appropriate.   
A general linear model (GLM) was used to compare variables for the treatment group to 
the control group at 3 months and at 6 months, adjusting for baseline. P-values <0.05 were 
considered statistically significant 
 
 
 
 
. 
 
 
 
 
CHAPTER 4. RESULTS 
A total of 342 dialysis subjects were screened for study eligibility; of these, sixty-
eight subjects (20%) met all study criteria. Reasons for non-participation, including exclusion 
criteria are given in Figures 1 and 2. Twenty-seven percent (80 patients) of those 
approached for study screening were not interested in participation and were not screened for 
eligibility. Interested subjects were verbally screened and consent for an intra-oral screening 
was obtained for those who met verbal criteria.  Of those screened verbally and (if eligible), 
by intra-oral examination, 26% met all inclusion criteria and agreed to participate in the 
study. Thirty-seven percent had less than 12 teeth and 10% did not meet age criteria (18-80 
years). Seventeen subjects failed to present for the baseline appointment (25% of those who 
initially agreed to participation). Fifty-one subjects were randomized (15% of approached 
patients).  Twenty-five subjects were randomized to the periodontal treatment group and 
twenty-six subjects were randomized to the control (delayed treatment) group. Full clinical 
parameters and serum samples were obtained for fifty-one subjects at baseline, for forty-six 
subjects at three months and for forty-one subjects at six months (Figure 1). Three subjects 
withdrew because they received kidney transplants, one subject became medically unstable 
(uncontrolled hypertension), five subjects failed multiple appointments and were dismissed 
and one subject died due to complications from general anesthesia during cardiac surgery. 
Twenty-eight total adverse events were reported among twenty-three subjects over the course 
of the study.  Thirteen events were among control subjects and fifteen events were among 
treatment group subjects. Twenty-four events were unrelated (for example: subject diagnosed 
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with hypothyroidism). Two mild events were probably related (dentinal sensitivity). Two 
events were possibly related (increase in probing depth, catheter infection). Ten unrelated 
events were classified as severe.  
 
 
 
Figure 1. Study summary. All data collected was used in analysis. 
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Figure 2. Status of screened subjects 
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            The mean age for participants was 54.1 (9.7) years and ranged from 30-75 years old. 
Treatment and control groups did not differ significantly at baseline by any variable 
measured (Table 1). Thirty-eight percent overall were female. Eleven percent of subjects 
were normal weight by body mass index (BMI), 47% were overweight and 42% were obese 
(WHO 2004). About one-third of subjects overall reported a history of heart disease. Mean 
time on dialysis was 42.5 months (about 3.5 years), with a range of 3 months to 176 months. 
Only 11% were current cigarette smokers. Eighty-five percent were on hemodialysis (versus 
peritoneal dialysis). The most common cause of kidney failure was hypertension, followed 
by diabetes. About half were diabetic overall, and it appears the diabetics were unevenly 
distributed between the control and treatment groups, with the treatment group containing 
64% of the diabetics and the treatment group containing only 36%. In other words, 73% of 
the treatment group were diabetic, but only 39% of the control group were diabetic (p=0.06). 
This uneven distribution approaches statistical significance and may have played a major role 
in the results. There were no significant differences between treatment and control group for 
any other characteristic at baseline. 
The overall mean number of teeth per subject was 23 (s.d. 5), mean extent bleeding 
on probing was 44 % (s.d. 23) and mean extent of plaque score >1 was 90% (s.d. 18).  On 
average, extent clinical attachment loss ≥3 was 41% (s.d. 26). Seventy five percent had 4 or 
more sites with ≥5mm probing depth. Mean baseline serum albumin was 4.14 (s.d. 0.12) for 
control group and 4.37 (s.d. 0.11) for the treatment group. Mean hsIL-6 was 6.35 (s.d. 1.54) 
for the control group and 10.2 (s.d. 3.19) for the treatment group. There were no significant 
differences between clinical periodontal parameters or serum markers at baseline, however 
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there were three serum albumin outliers. Excluding the outliers did not change the 
conclusions.  
 
Table 1. Baseline characteristics of control and treatment group subjects* 
Characteristic Overall 
Mean (SD) 
or % (n=51) 
Control 
Group Mean 
(SD) or % 
(n=26) 
Treatment 
Group Mean 
(SD) or % 
(n=25) 
p-values* 
Age (years) 54.1 (9.7) 53.9 (10.5) 54.3 (9.15) 0.90 
% Female 38 35 42 0.63 
% African American 87 87 88 0.48 
BMI 31.9 (7.6) 32.3 (6.7) 31.5 (8.42) 0.73 
% Diabetic 54 39 73 0.06 
% Hemodialysis 85 87 83 0.12 
% Current Smoker 11 9 13 0.86 
% Past Heart Disease 30 30 29 0.92 
Dialysis Vintage 
(months) 
42.5 (43.8) 45.7 (50.7) 38.8 (36.8) 0.59 
*Significance tests for comparisons between treatment and control group based on 2-sample 
t-test for continuous patient characteristics and Pearson’s chi-square test for categorical 
patient characteristics. None were statistically significant at p<0.05 
 
Clinical Parameters for treatment vs. control at 3 and 6 months 
 Table 2 summarizes the clinical periodontal parameters for control versus treatment 
group at baseline, 3 months and 6 months. GLM models were used at each time point to 
adjust for baseline values. At 3 months, there was a statistically significant improvement for 
the treatment group compared to the control group, adjusted for baseline, for the majority of 
the periodontal parameters: extent of probing depths ≥4mm (p=0.003), extent gingival index 
≥1 (p=0.003), extent plaque index ≥1 (p=0.006), mean attachment loss (p=0.01) and extent 
attachment loss ≥3mm (p=0.01). By 6 months, however, the difference between groups was 
no longer present for most variables. Only extent attachment loss ≥3mm was maintained at 6 
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months for the treatment vs. control group. Extent bleeding on probing and extent plaque 
score ≥1 were not statistically significantly different between the two groups at any time 
point. Adjusting for BMI, diabetic status, plaque index, disease level and response to therapy 
did not significantly alter results.  
Table 2:  Mean (StdErr) clinical measures for each time point by treatment group 
 
Characteristic Group Baseline* 
(n=51) 
3 
Months** 
(n=46) 
6 
Months** 
(n=41) 
p-value 
B/L-3m 
p-value 
B/L-6m 
Mean PD Control 2.96 (0.20) 2.85 (0.09) 2.71 (0.09)   
 Treatment 2.84 (0.14) 2.43 (0.10) 2.50 (0.09) 0.003 0.10 
Extent PD 
≥4mm 
Control 25.1 (4.72) 21.8 (2.18) 18.5 (2.10)   
 Treatment 23.2 (3.94) 12.1 (2.24) 12.8 (2.05) 0.003 0.06 
Extent BOP Control 40.4 (5.66) 38.6 (4.46) 35.7 (4.48)   
 Treatment 46.9 (4.22) 27.9 (4.57) 27.7 (4.37) 0.10 0.21 
Extent GI ≥1 Control 95.2 (2.27) 98.3 (2.72) 93.2 (3.29)   
 Treatment 96.6 (1.74) 86.9 (2.78) 89.0 (3.21) 0.006 0.36 
Extent PI ≥1 Control 87.1 (4.56) 89.5 (3.56) 86.5 (3.65)   
 Treatment 92.3 (3.20) 84.3 (3.64) 86.4 (3.56) 0.32 0.98 
Mean CAL Control 2.72 (0.26) 2.77 (0.13) 2.67 (0.15)   
 Treatment 2.52 (0.20) 2.29 (0.13) 2.35 (0.14) 0.01 0.13 
Extent CAL 
≥3mm 
Control 41.9 (5.53) 45.5 (3.61) 44.5 (3.80)   
 Treatment 40.4 (5.40) 31.5 (3.70) 33.9 (3.71) 0.01 0.05 
*No significant differences were found between groups at baseline 
**GLM Models adjusting for baseline values. 
 
Serum Albumin for treatment vs. control at 3 and 6 months 
 Table 3 summarizes the serum parameters for control versus treatment group at 
baseline, 3 months and 6 months. GLM models were used at each time point to adjust for 
baseline values. There was no difference between the groups for serum albumin or serum Il-6 
at any time point, when adjusted for baseline values. Adjusting for BMI, diabetic status, 
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disease level and response to therapy did not significantly alter results. No subjects improved 
from a serum albumin of less than 4 to greater than 4 during the course of the study. 
 
Table 3. Mean (StdErr) Serum Markers for Each Time Point by Treatment Group 
 
 Group Baseline* 
(n=51) 
3 
Months** 
(n=46) 
6 
Months** 
(n=41) 
p-value 
B/L-3M 
p-value 
B/L-6m 
Serum 
Albumin 
(g/dl) 
Control 4.16 (0.11) 4.11 (0.07) 4.03 (0.07)   
 Treatment 4.39 (0.10) 4.10 (0.07) 4.01 (0.07) 0.98 0.83 
Serum Il-6 
(pg/ml) 
Control 6.28 (1.36) 7.38 (1.27) 7.39 (1.14)   
 Treatment 10.2 (3.19) 7.25 (1.27) 7.17 (1.14) 0.94 0.89 
*No significant differences were found between groups at baseline 
**GLM Models adjusting for baseline values. 
 
Since diabetic status was not evenly distributed between the treatment and control 
group (p=0.06), further analysis was performed to compare treatment vs. control in diabetic 
subjects vs. non-diabetic subjects (Tables 4 and 5). Baseline serum albumin was 
significantly higher in the treatment vs. control group among the non-diabetics (p=0.001). No 
other baseline serum markers were significantly different. For both diabetics and non-
diabetics, in the treatment and control groups, there was a non-significant decrease in serum 
albumin.  For serum hsIl-6, while there were no statistically significant differences when 
separated by diabetic status, the pattern of response is notably different. Specifically, for 
diabetics, hsIl-6 increased from 3-6 months among the treatment group, but decreased among 
the controls. Conversely, for the non-diabetics, hsIl-6 decreased in the treatment group and 
increased in the control group. 
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Table 4.  Mean (StdErr) Serum Markers for Each Time Point by Treatment Group 
(Non-Diabetics) 
 
 Treatment 
Group 
Baseline 3-
Months** 
6-
Months** 
p-value 
B/L-3M 
p-value 
B/L-6m 
Serum 
Albumin 
(g/dl) 
Control 
(n=14) 
4.16 (0.12) 4.29 (0.09) 4.29 (0.10)   
 Treatment 
(n=8) 
4.90 
(0.14)& 
4.17 (0.14) 3.95 (0.15) 0.54 0.11 
Serum IL6 
(pg/ml) 
Control 
(n=14) 
7.12 (2.45) 6.54 (1.76) 8.13 (1.58)   
 Treatment 
(n=8) 
8.44 (4.67) 9.23 (2.33) 6.00 (2.33) 0.37 0.46 
&p=0.001 
**GLM Models adjusting for baseline values. 
 
 
 
Table 5.  Mean (StdErr) Serum Markers for Each Time Point by Treatment Group 
(Diabetics) 
 
 Treatment 
Group 
Baseline* 3-
Months** 
6-
Months** 
p-value 
B/L-3M 
p-value 
B/L-6m 
Serum 
Albumin 
(g/dl) 
Control 
(n=9) 
4.11 (0.24) 3.95 (0.13) 3.88 (0.11)   
 Treatment 
(n=16) 
4.10 (0.09) 3.99 (0.10) 3.91 (0.09) 0.82 0.87 
Serum IL6 
(pg/ml) 
Control 
(n=9) 
5.15 (1.10) 8.27 (1.46) 6.16 (1.63)   
 Treatment 
(n=16) 
11.1 (4.27) 6.44 (1.13) 7.70 (1.21) 0.34 0.46 
*No significant differences were found between groups at baseline 
**GLM Models adjusting for baseline values. 
 
 
 
 
 
 
CHAPTER 5. DISCUSSION 
 In this study, a round of intensive periodontal therapy (quadrant scaling and root 
planing with local delivery antibiotics) was not associated with an improvement in Il-6 or 
serum albumin levels at 3 or 6 months, despite improvements in periodontal therapy at 3 
months. Most benefits of therapy were lost by 6 months. Only extent attachment loss ≥3mm 
was maintained at 6 months for the treatment vs. control group. Control subjects also 
exhibited some improvement in clinical parameters, likely attributable to the Hawthorne 
effect.  
 Initial power calculations were based on 25 subjects per group, however, by 6 
months, only 20 subjects remained in the treatment group and 21 remained in the control 
group. Post hoc analysis of our data shows that in our sample, the power of detecting a 0.15 
observed difference is 0.14. Thus, this study did not have adequate power to detect 
differences between the groups in serum albumin; the results of this study serve as 
preliminary and feasibility data and provide insight into future study design. 
Patient characteristics may further explain the lack of treatment effect in our study.  
The ESRD patient population overall suffers from very high levels of multiple chronic 
diseases. Despite high levels of obesity in this sample, the assembled group appears to be 
relatively healthy.  The average baseline serum albumin for both groups is greater than 4 
mg/dl, which is commonly regarded as the goal serum albumin value. Further improvements 
in albumin levels beyond this goal would likely be clinically irrelevant and difficult to 
demonstrate.  Previous studies have shown an inverse relationship of periodontal disease 
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severity and  serum albumin [83], however, very few subjects in this sample presented with 
low (<4mg/dl) serum albumin. The high albumin levels may also be a marker for 
confounders that were not investigated in this study (for example, socioeconomic variables), 
and may also contribute to the relative healthiness of the population. All participants had the 
ability to attend multiple dental appointments, which is not necessarily the case for all 
dialysis patients.  
Furthermore, cytokine levels have been demonstrated to be influenced by both age 
and ethnicity. While still controversial, several studies have concluded that there is an 
increase in Il-6 with increasing age [86-88] as well as higher levels of Il-6 in African 
Americans as compared to whites [88]. Our sample had an average age of 54.1 years (s.d. 
9.7) and was 87% African American and potentially carry a higher inflammatory burden. 
While improvements in periodontal parameters were statistically significant at 3 
months, resolution of disease to levels generally considered to be consistent with 
maintenance of health was limited. Subjects had generally poor home care as indicated by 
high levels of plaque and BOP at baseline and 3 and 6 months. Improvements in periodontal 
health gained from treatment were detected at 3 months, but were lost by 6 months as the 
biofilm re-established.  This is likely related to a lack of periodontal maintenance and may 
account in part for lack of any detectable systemic response in this population, although 
stratifying by treatment response did not alter results. Positive treatment effects may have 
been seen at a shorter time interval when plaque and BOP levels were more likely to have 
been reduced. For future studies, a strict maintenance recall and shorter time interval for 
assessment may increase the likelihood of detecting treatment differences, which would 
underscore the critical role of professional biofilm disturbance. Furthermore, subjects were 
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instructed in the Bass Sulcular brushing technique, which is a relatively complicated 
technique to master. Use of a simpler brushing technique or use of an electric toothbrush may 
be a more realistic approach to home care in this population. 
 A recent study examined the impact of periodontal therapy on estimated glomerular 
filtration rate in healthy subjects with generalized severe periodontitis [89]. In this study, 
subjects with initially high plaque (65%) and bleeding scores (53.5%) were able to maintain 
a low (9%) plaque score and low bleeding score (7% and 5%, respectively) following scaling 
and root planing at 90 and 180 days with supragingival debridement at 1, 7, 30, 90 and 180 
days. In addition, subjects were given pre-therapy OHI and not provided with scaling and 
root planing until their plaque scores were below 20%. No subjects had renal dysfunction and 
there was a significant improvement in cystatin C- an alternative estimate of GFR [90] after 
30 days.  This study suggests periodontal therapy may have the capacity to impact kidney 
function. However, the change in cystatin c is small and other estimates of kidney function 
such as creatinine did not change. Furthermore, it suggests that good plaque control and strict 
maintenance in addition to scaling and root planing may be necessary to elicit changes. 
Interestingly, this group, similar to the dialysis population, did not demonstrate long-term 
improvement in systemic markers of inflammation (CRP) following therapy.  In contrast, 
D’Aiuto (2005) did detect changes in systemic inflammatory markers (Il-6) in healthy 
subjects with generalized severe periodontitis using a similar treatment regimen.  
The Periodontitis and Vascular Events (PAVE) study [76] used a similar treatment 
regimen and found that any periodontal therapy (including community provided therapy) 
compared to no treatment showed a significant reduction in the percentage of people with 
elevated CRP at 6 months. However, when the results were adjusted for obesity, the 
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association was no longer significant. Change in CRP among obese individuals was not 
observed. Evidence suggests that obesity itself is a chronic inﬂammatory state, indicated by 
increased expression, production, and release of inﬂammation-related adipokines, including 
tumor necrosis factor-, Il-6, plasminogen activating factor-1, haptoglobin, and leptin in 
obese individuals [91-94]. Adipose tissue is one of the main sources of inflammatory 
mediators in the body [95] and several studies have shown elevated Il-6 levels in obese 
patients [92]. BMI may also be associated with albumin levels [96-98] and so may also 
mediate changes in serum albumin.  In dialysis patients, BMI is used as a marker of energy 
nutritional status (energy stores) and is a complementary indicator of nutritional status to 
serum albumin. It has been independently associated with survival in dialysis patients. The 
presence of obesity may negate any positive impact of periodontal therapy [76]. Only 11% of 
subjects in our study were normal weight, with 47% overweight and 42% obese. Eleven 
percent of subjects had a BMI between 35-39.99 (WHO Class II obesity) and 11% had a 
BMI ≥40 (WHO Class III obesity).  Interestingly, studies show that both male and female 
dialysis patients in all age groups actually have a lower BMI as compared to a gender- and 
age-matched general population [99]. Given the abundance and severity of overweight and 
obese subjects in our study population, it is possible that this interfered with any reduction in 
Il-6.  
 Diabetic status is an additional factor which may have played a role in the results.  
Diabetes is often referred to as one of the most important systemic disease risk factors for 
periodontitis. Diabetes and periodontal disease have a complex interrelationship, with each 
impacting the other [100]. An  American Academy of Periodontology Commissioned Review 
[101] notes that “Over 200 articles have been published in the English literature over the past 
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50 years examining the relationship between these two chronic diseases.”  Diabetes induces 
changes in immune cell function and stimulates up-regulation of pro-inflammatory cytokines. 
This predisposes to chronic inflammation, progressive tissue breakdown, and diminished 
tissue repair capacity [102].  Reduced wound healing ability has a profound impact on 
periodontal disease expression as well as on response to periodontal therapy.  The level of 
control of diabetes may also play a role in response to periodontal therapy.  Diabetics were 
not assessed for level of diabetic control for this study. Diabetic subjects were unevenly 
distributed between the treatment and control groups, with more diabetics in the treatment 
group than in the control group. Given their diminished wound healing ability, diabetics tend 
to have a poorer response to periodontal therapy and may have dampened any treatment 
effects. When stratified by diabetic status, some interesting trends emerge. These trends are 
not statistically significant, but do show differences that potentially explain why the overall 
study did not show differences. Baseline serum albumin levels were significantly different 
between the non-diabetic treatment and control groups and the trends in serum marker levels 
differ when subjects are stratified by diabetic status.  The uneven distribution of diabetic 
subjects results in more stability for the diabetic treatment group, and the non-diabetic 
control group. Overall, serum albumin shows a non-significant decrease in all groups, with a 
slightly larger decrease in the non-diabetic treatment group. Kshirsagar et. al found an 
association between severe periodontitis and low serum albumin among patients on 
maintenance hemodialysis therapy, eight individual subjects had low (≤3.5g/dl) serum 
albumin at least one time point during the study (17%). Four subjects in this study had low 
serum albumin (<3.5g/dl) at baseline, five subjects had low serum albumin at 3 months, and 
seven had low serum albumin at 6 months. Three subjects had low serum albumin at every 
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time point, two subjects had low serum albumin at two time points and three subjects had 
low serum albumin at only one time point. To our knowledge, no other studies have 
investigated changes in serum albumin levels following periodontal therapy.   
Interestingly, Il-6 also has a non-significant decrease overall. In apparently healthy 
patients, average Il-6 level was 1.77pg/ml with a range of 0.45-9.96pg/ml . Our sample had 
an average Il-6 of 6.28pg/ml (s.d. 1.36) in the control group and 10.2pg/ml in the treatment 
group, which is higher than the average, potentially reflecting an increased systemic 
inflammatory burden among these subjects. When the treatment and control groups are 
stratified by diabetic status, there are some conflicting results. Among the diabetics, Il-6 
initially fell in the treatment group by 3 months, but then rebounded by 6 months; while 
among the non-diabetics, Il-6 initially increased in the treatment group by 3 months, and then 
decreased by 6 months. Other studies show a transient elevation of Il-6 and inflammatory 
markers following periodontal therapy [103]  up to 120 minutes, but longer term studies have 
conflicting findings on the impact of periodontal therapy on Il-6 and other inflammatory 
markers in healthy and medically compromised populations [32, 76, 104-107].  
Periodontal disease is only one potential source of inflammation in this population 
with multiple co-morbidities. While periodontal disease is potentially a modifiable 
contributor to the systemic inflammatory burden, it is likely to require a strict plaque control 
maintenance protocol and potentially more invasive therapy to improve periodontal status to 
a level consistent with periodontal health. Furthermore, the influence of other chronic 
inflammation-related disease may overwhelm the impact of periodontal disease; thus control 
of systemic factors including obesity and diabetes is critical in assessing the impact of 
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periodontal therapy on systemic markers of inflammation and metabolism in the dialysis 
population.  
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